- Report
- February 2026
- 250 Pages
Global
From €4021EUR$4,490USD£3,467GBP
- Report
- March 2026
- 179 Pages
Global
From €5238EUR$5,850USD£4,517GBP
- Report
- May 2025
- 106 Pages
Global
From €4253EUR$4,750USD£3,667GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3224EUR$3,600USD£2,780GBP
- Report
- February 2024
- 150 Pages
Global
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 181 Pages
Europe
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 80 Pages
Europe
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Germany
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Italy
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Oman
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
France
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Russia
From €4253EUR$4,750USD£3,667GBP
- Report
- February 2024
- 70 Pages
Japan
From €4253EUR$4,750USD£3,667GBP

Tresiba is a brand of long-acting insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a basal insulin, meaning it is taken once or twice daily to provide a steady, low level of insulin throughout the day. It is used to control blood sugar levels in adults and children with type 1 and type 2 diabetes. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes. Tresiba is available in both a pen and a vial form, and is taken in combination with other diabetes medications.
The Tresiba market is a competitive one, with several companies offering similar products. These include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Each company offers a range of long-acting insulin products, including Tresiba, to meet the needs of people with diabetes. Show Less Read more